Efficacy and Safety of Ginkgo Biloba Standardized Extract (24% Ginkoflavonoglicozides and 6% Terpenes) in Treatment of Mild Cognitive and Concentration Impairment

NCT00446485 Phase 4 COMPLETED

The purpose of the study is to determine weather Ginkgo biloba standardized extract (24% ginkoflavonoglicozides and 6% terpenes) is effective in treatment of cognitive and concentration impairment

Details

Lead sponsor	Milsing d.o.o.
Phase	Phase 4
Status	COMPLETED
Enrolment	90
Start date	2007-05
Completion	2010-04

Conditions

• Mild Cognitive Impairment
• Cerebrovascular Insufficiency

Interventions

• Ginkgo biloba standardized extract 24/6
• Ginkgo Biloba standardized extract 24/6
• placebo

Primary outcomes

• Changes of MDRS — 6 months
• Changes of VFT — 6 months
• Changes of CGI — 6 months
• Changes of SCAG — 6 months
• Changes of MMSE — 6 months

Countries

Croatia